Data Map
According to the official website of the National Medical Security Bureau, the work of the National Medical Insurance Drug Catalog was officially concluded on January 8.The person in charge of the Medical Management Department of the State Medical Security Bureau introduced the situation related to the negotiations of the new crown therapy for the medical insurance drug catalog.
This year, there are three new crown therapy drugs for Azf's fixed tablet, Namartovir Film/Litonovir Film (hereinafter referred to as "PAXLOVID"), and clear lung detox particles.Expert review and other procedures participated in the negotiations.Among them, the negotiations of Azf's fixed slices and lung detoxification particles were successfully negotiated, and PAXLOVID failed to succeed due to high quotations in production enterprise Pfizer Investment Co., Ltd. The person in charge said that although Paxlovid failed to include the medical insurance directory through negotiations, according to the recently issued by the State Medical Insurance Administration and relevant departments, the "Class B tube" was optimized after the implementation of the "Class B tube".Notice of guarantee related policies (hereinafter referred to as notification) requirements, all therapeutic drugs in the new coronary virus infection diagnosis and treatment plan (trial tenth edition), including PaxLovid, Azf fixed tablet, Monorawa capsule, scattered, scatteredCold dampness particles, etc., medical insurance will be paid temporarily until March 31, 2023.During this period, patients with new crown virus infection can enjoy medical insurance reimbursement policies with these drugs. In addition, after the negotiations were included in the national medical insurance drug catalog after this negotiation, more than 600 drugs such as the treatment of fever and cough have been treated in the national medical insurance drug directory.At the same time, in order to meet the needs of patients with new crown virus infection in various places, the medical insurance departments in various places have recently incorporated a number of new crown -symptomatic treatment drugs into the scope of medical insurance payment in the region.Generally speaking, the treatment of new crown virus infection for medical insurance reimbursement is abundant.The person in charge also said that the recent guidelines for the formation of new crown therapy drug prices (trial) issued by the Office of the State Medical Insurance Administration (trial).Reasonable pricing.In the next step, the National Medical Insurance Administration will continue to adhere to the people -centered, implement the decision -making and deployment of the Party Central Committee and the State Council, make every effort to adjust the medical insurance and drug catalog, incorporate more new drugs and good medicines into the medical insurance catalog, and effectively reduce the burden of seeking medical treatment for the masses.Help solve the worries of the people after seeing a doctor.Source: official website of the National Medical Security Bureau
